Restoring Atrial Function.
Reimagining Heart Failure Care.

The Next CRT Evolution in Heart Failure Care:
Treating the Atrium

Heart failure care is evolving.
It’s time to look beyond the ventricles—because the left atrium plays a central role in disease progression, especially in patients with heart failure with preserved ejection fraction (HFpEF).

At MaxWell Biomedical, we’re pioneering a bold new approach:
CRT-A: Cardiac Resynchronization Therapy for the Atrium.

Why the Atrium? Why Now?

HFpEF is a dual-chamber disease—yet current therapies ignore the atrium.

But evidence is clear:

  • Atrial dysfunction drives symptoms

  • It fuels arrhythmias like AF

  • And it accelerates clinical decline

Rhythm360™: Intelligent, Multi-Mode Therapy

Our implantable Rhythm360™ system is the first of its kind—designed to restore normal atrial function with four integrated therapeutic modes:

  1. Prevention – Pacing that senses and suppresses AF triggers before they strike

  2. Restoration – Painless rhythm termination without ablation or shock

  3. LA Reset – Low-energy cardioversion from within the atrium

  4. BBp – Bachmann’s Bundle pacing to restore synchrony and AV timing.

Together, these modes form a closed-loop system that adapts to the patient in real time, aiming for sustained sinus rhythm without tissue damage.

  • Exciting News from MaxWell Biomedical!

    Maxwell Biomedical is expanding its ongoing clinical study to further validate the groundbreaking Spatial Resynchronization Therapy (SRT) for patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF).
    SRT is designed to imperceptibly terminate AF and restore atrial function and atrial synchrony —a non-destructive, next-generation approach that sets it apart from conventional ablation therapies. With this expansion, we aim to accelerate clinical insights, broaden patient access, and drive a paradigm shift in AF treatment for the AF-HFpEF population.

    Why It Matters:
    ·        Better Outcomes – SRT enhances atrial heart function while preventing AF, addressing a critical unmet need.
    ·        Expanded Study Scope – More patients, more data, stronger clinical validation.
    ·        Innovative Non-Destructive Approach – Unlike ablation, SRT does not destroy cardiac tissue but restores atrial conduction.

    As we take this next step, we’re grateful for our investors, clinical partners, and dedicated team members working to bring a new era of AF treatment to patients worldwide.

    Stay tuned for more updates!
    March 13, 2025

Active Atrial Fibrillation Management

Transforming AF Care: A Device Approach That Overcomes Past Limitations

Maximum Wellness

[ mak-suh-muhm ] [ wel-nis ]

Decades of AF Treatment Have Focused Soley on Tissue Destruction

Medicine Evolves: 🟥 Cox-Maze Surgery (1980s) →🟧 Catheter Ablation (1990s–Present) →🟩 Non-destructive (Future)